☆ 4.1 Letter

Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum

REVUE NEUROLOGIQUE (2020)

期刊

REVUE NEUROLOGIQUE

卷 176, 期 6, 页码 522-525

出版社

MASSON EDITEUR

DOI: 10.1016/j.neurol.2020.04.009

关键词

-

类别

Clinical Neurology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Pharmacology & Pharmacy

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Nina M. Bemben, Melody L. Berg

Summary: This review evaluates the efficacy of inactivated vaccines in immunocompromised patients treated with immunosuppressive drugs for various conditions. The majority of studies suggest an attenuated immune response to inactivated vaccines, with anti-B-cell antibodies having a more severe and prolonged negative effect on vaccine efficacy.

PHARMACOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy

Masafumi Seki, Kosuke Hashimoto, Nami Kondo, Yoshitaka Ohya, Futoshi Kotajima, Kotaro Mitsutake

Summary: The treatment regimen for COVID-19 patients with hematological malignancies remains unclear. This study suggests that starting with antiviral agents followed by corticosteroids and immunosuppressive agents may be more effective in controlling inflammation in these patients.

INFECTION AND DRUG RESISTANCE (2022)

添加到收藏夹

Article Pediatrics

COVID-19 in children treated with immunosuppressive medication for kidney diseases

Matko Marlais, Tanja Wlodkowski, Samhar Al-Akash, Petr Ananin, Varun Kumar Bandi, Veronique Baudouin, Olivia Boyer, Luciola Vasquez, Sukanya Govindan, Nakysa Hooman, Iftikhar Ijaz, Reyner Loza, Marta Melgosa, Nivedita Pande, Lars Pape, Anshuman Saha, Dmitry Samsonov, Michiel F. Schreuder, Jyoti Sharma, Sahar Siddiqui, Rajiv Sinha, Heather Stewart, Velibor Tasic, Burkhard Toenshoff, Katherine Twombley, Kiran Upadhyay, Marina Vivarelli, Donald J. Weaver, Robert Woroniecki, Franz Schaefer, Kjell Tullus

Summary: This study examined the clinical course of COVID-19 in children with kidney disease who were taking immunosuppressive medication, finding that most of these children had mild cases of the disease. The study suggests that children on immunosuppressive therapy should not be isolated more strictly than those who are not receiving such treatment.

ARCHIVES OF DISEASE IN CHILDHOOD (2021)

添加到收藏夹

Article Biochemical Research Methods

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19

Jens Martens-Lobenhoffer, Corinna R. Boger, Jan Kielstein, Stefanie M. Bode-Bo

Summary: A LC-MS/MS method for quantifying nirmatrelvir and ritonavir in human plasma of COVID-19 patients treated with Paxlovid (R) was developed, showing good accuracy and precision in therapeutic drug monitoring.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2022)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment

Tatjana Welzel, Samuel Dembi Samba, Reinhild Klein, Johannes N. van den Anker, Jasmin B. Kuemmerle-Deschner

Summary: This case series presents COVID-19 outcomes in patients with IL-1-mediated and unclassified AID receiving immunosuppressive therapy. Although all patients had a mild course of COVID-19, some patients experienced increased AID activity post-recovery. Further research is needed to understand disease progression and immunity after COVID-19 in AID patients.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Cumali Efe, Craig Lammert, Koray Tascilar, Renumathy Dhanasekaran, Berat Ebik, Fatima Higuera-de la Tijera, Ali R. Caliskan, Mirta Peralta, Alessio Gerussi, Hatef Massoumi, Andreea M. Catana, Tugrul Purnak, Cristina Rigamonti, Andres J. G. Aldana, Nidah Khakoo, Leyla Nazal, Shalom Frager, Nurhan Demir, Kader Irak, Zeynep Melekoglu-Ellik, Huseyin Kacmaz, Yasemin Balaban, Kadri Atay, Fatih Eren, Mario R. Alvares-da-Silva, Laura Cristoferi, Alvaro Urzua, Tugce Eskazan, Bianca Magro, Romee Snijders, Sezgin Barutcu, Ellina Lytvyak, Godolfino M. Zazueta, Aylin Demirezer-Bolat, Mesut Aydin, Alexandra Heurgue-Berlot, Eleonora De Martin, Nazim Ekin, Sumeyra Yildirim, Ahmet Yavuz, Murat Biyik, Graciela C. Narro, Murat Kiyici, Murat Akyildiz, Evrim Kahramanoglu-Aksoy, Maria Vincent, Rotonya M. Carr, Fulya Gunsar, Eira C. Reyes, Murat Harputluoglu, Costica Aloman, Nikolaos K. Gatselis, Yucel Ustundag, Javier Brahm, Nataly C. E. Vargas, Fatih Guzelbulut, Sandro R. Garcia, Jonathan Aguirre, Margarita Anders, Natalia Ratusnu, Ibrahim Hatemi, Manuel Mendizabal, Annarosa Floreani, Stefano Fagiuoli, Marcelo Silva, Ramazan Idilman, Sanjaya K. Satapathy, Marina Silveira, Joost P. H. Drenth, George N. Dalekos, David N. Assis, Einar Bjornsson, James L. Boyer, Eric M. Yoshida, Pietro Invernizzi, Cynthia Levy, Aldo J. Montano-Loza, Thomas D. Schiano, Ezequiel Ridruejo, Staffan Wahlin

Summary: The study found that AIH patients who were on systemic glucocorticoids or thiopurines before the onset of COVID-19 had significantly worse severity of the disease, while those on baseline treatment with mycophenolate mofetil or tacrolimus also experienced more severe COVID-19 courses in a smaller subset of treated patients.

LIVER INTERNATIONAL (2022)

添加到收藏夹

Article Oncology

Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy

Haris Hatic, Kristine R. R. Hearld, Devika Das, Jessy Deshane

Summary: Patients with cancer who contract COVID-19 while receiving chemotherapy or immune checkpoint inhibitors (ICIs) are at higher risk of complications and mortality. This retrospective study found that COVID-19-related ICI mortality was higher compared to patients receiving chemotherapy. However, patients with better functional status and COVID-19 vaccination had reduced mortality.

CANCERS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Oncologic immunomodulatory agents in patients with cancer and COVID-19

Justin Jee, Aaron J. Stonestrom, Sean Devlin, Teresa Nguyentran, Beatriz Wills, Varun Narendra, Michael B. Foote, Melissa Lumish, Santosha A. Vardhana, Stephen M. Pastores, Neha Korde, Dhwani Patel, Steven Horwitz, Michael Scordo, Anthony F. Daniyan

Summary: This retrospective study investigated the impact of different medications commonly used in cancer treatment on the outcomes of cancer patients infected with SARS-CoV-2. The results suggested that corticosteroid administration may lead to worse outcomes in some cases, while the effects of chemotherapy or immunotherapy on the prognosis of COVID-19 in cancer patients remain unclear.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Letter Immunology

Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids

Jani M. Kim, Geetha Sivasubramanian

Summary: The widespread use of corticosteroids for COVID-19 treatment has resulted in the reactivation of Strongyloides and the occurrence of severe disease in patients from endemic areas. We report a case of a US patient with COVID-19 and Strongyloides hyperinfection syndrome, and review other reported cases. Our findings emphasize the importance of Strongyloides screening and treatment in high-risk populations.

EMERGING INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Virology

Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients

Elliot H. Akama-Garren, Jonathan X. Li

Summary: A retrospective study found that COVID-19 patients who were previously on immunosuppressive therapies had higher mortality rates, with laboratory markers indicating a more severe clinical presentation. This highlights the importance of aggressive monitoring and supportive care for immunosuppressed patients diagnosed with COVID-19.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Rheumatology

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab

Cathy Mireille Melong Pianta Taleng, Kim Lauper, Benoit Gilbert, Tim Cunningham, Romain Guemara, Laure Brulhart, Diana Dan, Delphine Courvoisier, Axel Finckh

Summary: This study aimed to compare the severity of COVID-19 between patients with inflammatory autoimmune diseases treated with rituximab (RTX) and those treated with anticytokine therapies, such as Tumor Necrosis Factor (TNF) inhibitors. Results showed that while the overall incidence of COVID-19 symptoms was similar between the RTX and IFX groups, the incidence of severe COVID-19 tended to be higher in the RTX group.

RMD OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis

Fabrizio Esposito, Harald Matthes, Friedemann Schad

Summary: This study suggests that targeting C-reactive protein (CRP) in the early stages of severe COVID-19 could be a potential therapeutic approach. By performing selective CRP apheresis, the plasma levels of CRP can be significantly reduced, leading to improvements in patient outcomes and a lower mortality rate.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Pediatrics

Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders

Parniyan Sadeghi, Parmida Sadat Pezeshki, Nima Rezaei

Summary: COVID-19 infection in pediatric patients with autoimmune disorders is a particular concern as these patients are at a higher risk for complications due to the underlying autoimmune diseases and immunomodulatory drugs they take. However, there is limited research on this group of children as they are underrepresented in COVID-19 studies. The severity of COVID-19 in pediatric patients with autoimmune disorders is highly dependent on the type and severity of their autoimmune disease, as well as the medication they are taking.

EUROPEAN JOURNAL OF PEDIATRICS (2023)

添加到收藏夹

Article Microbiology

Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma

Armando M. Perichon, Andrea Acosta, Liliana Di Tulio, Maria Jose Munuce, Stella Pezzotto, Oscar Bottasso, Esteban C. Nannini

Summary: Early treatment with convalescent plasma (CP) within 3 days of hospitalization is associated with reduced 28-day mortality in hospitalized COVID-19 patients. This suggests that CP may be a relatively safe, cheap, and potentially effective therapeutic option.

MBIO (2023)

添加到收藏夹

Article Oncology

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, Carlo Alberto Tondini, Joseph M. Grimes, Megan H. Trager, Sharon Nahm, Leyre Zubiri, Michael Manos, Peter Bowling, Arielle Elkrief, Neha Papneja, Maria Grazia Vitale, April A. N. Rose, Jessica S. W. Borgers, Severine Roy, Joanna Mangana, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Alon Vaisman, Samuel D. Saibil, Marcus O. Butler, Alexander M. Menzies, Matteo S. Carlino, Michael Erdmann, Carola Berking, Lisa Zimmer, Dirk Schadendorf, Laura Pala, Paola Queirolo, Christian Posch, Axel Hauschild, Reinhard Dummer, John Haanen, Christian U. Blank, Caroline Robert, Ryan J. Sullivan, Paolo Antonio Ascierto, Wilson H. Miller, F. Stephen Hodi, Karijn P. M. Suijkerbuijk, Kerry L. Reynolds, Osama E. Rahma, Paul C. Lorigan, Richard D. Carvajal, Serigne Lo, Mario Mandala, Georgina Long

Summary: This study investigated the impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 in cancer patients infected with SARS-CoV-2. The findings showed that mortality related to COVID-19 in ICI-treated cancer patients did not appear to be higher than previously reported rates for cancer patients, although inpatient mortality was high compared to hospitalized cancer patients overall. Factors associated with adverse outcomes in ICI-treated patients with COVID-19 were also identified.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Comparative effectiveness of dimethyl fumarate in multiple sclerosis

Pauline Bosco-Levy, Marc Debouverie, Bruno Brochet, Francis Guillemin, Celine Louapre, Elisabeth Maillart, Olivier Heinzlef, Severine Lignot, Pauline Diez, Abdelilah Abouelfath, Regis Lassalle, Patrick Blin, Cecile Droz-Perroteau

Summary: DMF significantly reduced the risk of treated relapse compared to first-line RRMS agents (TERI and IIM) for patients with RRMS. There was no significant difference in the risk of disability progression among the matched cohorts.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Celine Louapre, Michella Ibrahim, Elisabeth Maillart, Basma Abdi, Caroline Papeix, Bruno Stankoff, Anne-Laure Dubessy, Caroline Bensa-Koscher, Alain Creange, Zina Chamekh, Catherine Lubetzki, Anne-Genevieve Marcelin, Jean-Christophe Corvol, Valerie Pourcher

Summary: SARS-CoV-2 antibody response was reduced in patients with MS or NMO-SD treated with anti-CD20 therapies, suggesting the need for long-term monitoring of reinfection risk and specific vaccination strategies in this population.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

添加到收藏夹

Article Clinical Neurology

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Edouard Januel, Jerome De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, Xavier Moisset, Caroline Bensa, Adil Maarouf, Jean Pelletier, Sandra Vukusic, Bertrand Audoin, Celine Louapre

Summary: Recent studies suggest a lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination in patients treated with anti-CD20 and fingolimod. This study evaluated cases of COVID-19 occurring after vaccination among patients with MS and NMO, finding mild severity in cases reported. The results emphasize the need for a third COVID-19 vaccine dose for anti-CD20 treated patients and call for further prospective studies on vaccine efficacy in MS and NMO patients.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Review Clinical Neurology

Genetics and familial distribution of multiple sclerosis: A review

A. Balcerac, C. Louapre

Summary: This article reviews the genetics of multiple sclerosis (MS) and the clinical correlations between different members of a family. Specific genes have been found to influence the clinical or radiological presentation of MS, and correlations have been observed in familial forms of MS. The genetic contribution to the risk of developing MS is estimated to be about 50%, with the genes mainly located within the major histocompatibility complex. Familial MS represents 12.6% of all MS cases and has different clinical features compared to sporadic cases.

REVUE NEUROLOGIQUE (2022)

添加到收藏夹

Article Neurosciences

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

Bruno Brochet, Pierre Clavelou, Gilles Defer, Jerome De Seze, Celine Louapre, Eloi Magnin, Aurelie Ruet, Catherine Thomas-Anterion, Patrick Vermersch

Summary: This literature review focuses on the cognitive deficits observed in secondary progressive multiple sclerosis (SPMS). The findings suggest that cognitive disorders are more frequent and severe in SPMS compared to relapsing-remitting MS (RRMS), and the profile of cognitive impairment differs between these two phenotypes.

BRAIN SCIENCES (2022)

添加到收藏夹

Review Clinical Neurology

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean-Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F. Farez, Massimo Filippi, Kathryn C. Fitzgerald, Mattia Fonderico, Riadh Gouider, Yael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frenay, Celine Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, Maria Isabel Zuluaga Rodas, Mar Tintore, Bruno Stankoff

Summary: In recent years, there have been rapid developments in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), with a wide range of disease-modifying treatments (DMTs) now available. However, most DMTs come with the risk of adverse events, particularly infections. To address this, an international workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in April 2021 to review the current knowledge on infection risks associated with DMT use in MS and NMOSD patients, and to discuss strategies for risk mitigation. The workshop also explored specific populations, such as children, pregnant women, individuals with comorbidities, and those living in regions with high infection burden, as well as the impact of the ongoing SARS-CoV-2 pandemic on DMT-associated infectious risks.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Article Clinical Neurology

Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis A Retrospective Study

Vito A. G. Ricigliano, Celine Louapre, Emilie Poirion, Annalisa Colombi, Arya Yazdan Panah, Andrea Lazzarotto, Emanuele Morena, Elodie Martin, Michel Bottlaender, Benedetta Bodini, Danielle Seilhean, Bruno Stankoff

Summary: By using MRI and PET imaging, this study found changes in the choroid plexus (CP) in patients at the earliest stage of multiple sclerosis (MS), including larger CP volume and higher inflammation response. These findings suggest that CP imaging may serve as an early biomarker for MS and support the involvement of blood-CSF barrier dysfunction in disease development.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

添加到收藏夹

Article Peripheral Vascular Disease

Structural and functional analysis of retinal vasculature in HANAC syndrome with a novel intronic COL4A1 mutation

Celine Faure, Cindy Castrale, Anais Benabed, Pauline Cognard, Romain Leze, Daniela Castro-Farias, Marion Gerard, Celine Louapre, Michel Paques

Summary: This study reported a HANAC patient family associated with a mutation in the COL4A1 gene. The structure and function of retinal vessels in patients were analyzed using imaging techniques. The results showed not only typical retinal arteriolar tortuosity, but also other vascular abnormalities, which were more pronounced in older patients.

MICROVASCULAR RESEARCH (2023)

添加到收藏夹

Article Clinical Neurology

Positron Emission Tomography with [18F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression

Mariem Hamzaoui, Jeanne Garcia, Giacomo Boffa, Andrea Lazzarotto, Martina Absinta, Vito A. G. Ricigliano, Theodore Soulier, Matteo Tonietto, Philippe Gervais, Anne Bissery, Celine Louapre, Michel Bottlaender, Benedetta Bodini, Bruno Stankoff

Summary: This study examines the prognostic value of persisting neuroinflammation in multiple sclerosis (MS) lesions using [F-18]-DPA-714-PET. The results show that a high proportion of non-gadolinium-enhancing lesions have persisting neuroinflammation, which predicts atrophy and clinical progression in MS patients.

ANNALS OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization

Celine Louapre, Lisa Belin, Stephane Marot, Amandine Hippolyte, Edouard Januel, Michella Ibrahim, Lina Jeantin, Karen Zafilaza, Isabelle Malet, Fanny Charbonnier-Beaupel, Michelle Rosenzwajg, Cathia Soulie, Anne-Genevieve Marcelin, Valerie Pourcher

Summary: This study evaluated the serological response and neutralizing activity of a modified SARS-CoV-2 vaccine regimen in multiple sclerosis (MS) patients. The results showed that after receiving the enhanced vaccination, the antibody response and neutralizing activity improved in patients treated with anti-CD20. However, the neutralizing activity against the Omicron variant remained low.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis

C. Louapre, M. Rosenzwajg, M. Golse, A. Roux, F. Pitoiset, L. Adda, N. Tchitchek, C. Papeix, E. Maillart, A. Ungureanu, F. Charbonnier-Beaupel, D. Galanaud, J. C. Corvol, E. Vicaut, C. Lubetzki, D. Klatzmann

Summary: The effect of low-dose interleukin-2 (IL2(LD)) treatment on regulatory T cells (Tregs) in multiple sclerosis (MS) patients was modest and delayed, compared to other autoimmune diseases. Larger studies with increased dosages and/or modified modalities of administration are needed.

JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis

Edouard Januel, David Hajage, Pierre Labauge, Elisabeth Maillart, Jerome De Seze, Helene Zephir, Jean Pelletier, Laurent Guilloton, Caroline Bensa, Olivier Heinzlef, Olivier Casez, Damien Biotti, Bertrand Bourre, Sandra Vukusic, Aude Maurousset, Eric Berger, David Laplaud, Christine Lebrun-Frenay, Anne-Laure Dubessy, Pierre Branger, Eric Thouvenot, Pierre Clavelou, Francois Sellal, Eric Manchon, Thibault Moreau, Caroline Papeix, Florence Tubach, Celine Louapre

Summary: In patients with multiple sclerosis (MS), anti-CD20 therapies and neurologic disability are associated with severe COVID-19. However, it is unclear whether these factors are independently associated with severe COVID-19 or if the association depends on the clinical course of MS.

JAMA NETWORK OPEN (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

An imaging signature in choroid plexuses in pre-symptomatic multiple sclerosis

Vito Ricigliano, Arya Yazdan-Panah, Andrea Lazzarotto, Michel Bottlaender, Benedetta Bodini, Celine Louapre, Bruno Stankoff

NEUROLOGY (2022)

添加到收藏夹

Meeting Abstract Ophthalmology

Detecting inflammatory cells in patients with Multiple Sclerosis using AO-SLO phase contrast imaging

Elena Gofas, Celine Louapre, Nathaniel Norberg, Ysoline Beigneux, Michel Paques, Catherine Vignal Clermont, Kate Grieve

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2022)

添加到收藏夹

Meeting Abstract Clinical Neurology

Impaired antisaccades are more strongly associated with fatigue score than cognitive impairment in multiple sclerosis

M. Ibrahim, A. Lanore, M. Glachant, S. Taeib-Tamacha, A. Balcerac, Y. Beigneux, P. Pouget, C. Louapre

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.